Mirum Pharmaceuticals, Inc.
MIRMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. With a market capitalization of $5.22B, it sits in mid-cap territory. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Market Cap
$5.22B
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
-114.03
EPS (TTM)
$-14.10
EPS (Fwd)
$-0.70
ROE
-703.0%
ROA
-6.8%
Cash
$438.3M
Total Debt
$762.9M
Free CF
$76.6M
52W Change
12.3%
Annual Financials
Cash vs Debt
Where MIRM stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, MIRM finished 19.98% below its 150-day moving average ($99.93) and 18.82% below its 200-day moving average ($98.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MIRM overbought or oversold?
At the October 15, 2026 close, MIRM's RSI(14) was 30.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $438.3M in cash, though total debt stands at $762.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $76.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -703.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $77.1M (2022) to $521.3M (2025), reflecting a 576% increase over the period.
With a beta below 0.7, Mirum Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing MIRM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.